Publication Name	World Journal of Experimental Medicine
Manuscript ID	95272
Country	Egypt

Received	2024-04-10 22:19
Peer-Review Started	2024-04-10 22:19
To Make the First Decision
Return for Revision	2024-08-12 06:26
Revised	2024-08-18 14:20
Second Decision	2024-08-28 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-28 09:27
Articles in Press	2024-08-28 09:27
Publication Fee Transferred
Edit the Manuscript by Language Editor	2024-09-27 16:12
Typeset the Manuscript	2024-09-30 12:31
Publish the Manuscript Online	2024-10-31 07:40

ISSN	2220-315x (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Clinical Trials Study
Article Title	Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis
Manuscript Source	Invited Manuscript
All Author List	Zeinab Seif El-Din, Mohammed Afify, Essam Zayed, Dalia Elsabaawy, El Sayed Tharwa, Ahmed Elsharawy, Eman Abdelsameea and Mohamed Akl Rady
ORCID	Author(s) ORCID Number Eman Abdelsameea http://orcid.org/0000-0002-3225-7164
Funding Agency and Grant Number
Corresponding Author	Eman Abdelsameea, MD, Editor-in-Chief, Full Professor, Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Gamal Abd-Elnasser Street, Shebin El-Kom 32511, Egypt. eabdelsameea@liver-eg.org
Key Words	Dapagliflozin; Cirrhosis; Diabetes mellitus; Hemoglobin; Liver diseases
Core Tip	We aim to assess effectiveness and safety of dapagliflozin in co management of diabetes mellitus and cirrhosis with or without ascites. Studied patients were divided into 2 groups: 100 patients as control group received insulin, 200 patients were given dapagliflozin. On follow up, there was significant higher incidence of hypoglycemia, hepatic encephalopathy, variceal bleeding and urinary tract infection in insulin group than dapagliflozin group. Frequent micturition and vertigo were significantly higher in dapagliflozin group. Dapagliflozin was safe and effective in treatment of diabetic patients who have cirrhosis with improvement of ascites, decrease in diuretic dose and Child Pugh score.
Publish Date	2024-10-31 07:40
Citation	<p>Seif El-Din Z, Afify M, Zayed E, Elsabaawy D, Tharwa ES, Elsharawy A, Abdelsameea E, Rady MA. Dapagliflozin as an oral antihyperglycemic agent in the management of diabetes mellitus in patients with liver cirrhosis. <i>World J Exp Med</i> 2024; 14(4): 95272</p>
URL	https://www.wjgnet.com/2220-315x/full/v14/i4/95272.htm
DOI	https://dx.doi.org/10.5493/wjem.v14.i4.95272

Full Article (PDF)	WJEM-14-95272-with-cover.pdf
CONSORT 2010 Statement	95272-CONSORT-2010-statement.pdf
Manuscript File	95272_Auto_Edited_033116.docx
Answering Reviewers	95272-answering-reviewers.pdf
Audio Core Tip	95272-audio.mpeg
Biostatistics Review Certificate	95272-biostatistics-statement.pdf
Clinical Trial Registration Statement	95272-clinical-trial-registration-statement.pdf
Conflict-of-Interest Disclosure Form	95272-conflict-of-interest-statement.pdf
Copyright License Agreement	95272-copyright-assignment.pdf
Signed Informed Consent Form(s) or Document(s)	95272-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	95272-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	95272-non-native-speakers.pdf
Peer-review Report	95272-peer-reviews.pdf
Scientific Misconduct Check	95272-scientific-misconduct-check.png
Scientific Editor Work List	95272-scientific-editor-work-list.pdf
CrossCheck Report	95272-crosscheck-report.pdf